Last updated: February 20, 2026
What is the scope of EP2734522?
European Patent EP2734522, titled "Method for increasing the expression of a target gene in a cell," claims a novel genetic engineering method broadly applicable to increasing expression of specific genes in mammalian cells. The patent primarily targets biotech applications, including gene therapy, cell-based assays, and biopharmaceutical production.
The patent's scope encompasses:
- Use of specific nucleic acid constructs encoding regulatory elements.
- Methods of delivering these constructs into cells via vectors or direct transfection.
- Techniques to enhance transcriptional activity of target genes in mammalian cells.
- Potential applications in therapeutic contexts, such as treating genetic disorders or boosting protein production.
The patent does not claim specific vector backbones or gene sequences but emphasizes the methods of controlling gene expression levels through regulatory sequences and delivery methods.
What are the core claims of EP2734522?
The individual claims are divided into independent and dependent claims that specify the inventive concept. The most critical claims are as follows:
- Claim 1: Describes a method involving introducing a nucleic acid construct comprising a regulatory element operably linked to a gene of interest into a mammalian cell, with the aim of increasing expression compared to a control.
- Claim 2: Specifies that the regulatory element can be a promoter, enhancer, or other cis-acting element capable of augmenting transcription.
- Claim 3: Covers various delivery methods, including viral vectors, plasmids, or direct nucleic acid transfection.
- Claim 7: Includes the use of specific regulatory sequences identified in the specification, such as enhancer sequences derived from certain genomic regions.
- Claim 10: Describes a cell genetically modified to contain the nucleic acid construct and express the target gene at elevated levels.
Dependent claims cover specifics like vector types, sequences, and application contexts, reinforcing the method's versatility.
How broad is the patent's claim coverage?
EP2734522’s claims are intended to cover a broad range of gene expression enhancement techniques. The emphasis on general regulatory elements and various delivery methods introduces significant breadth:
- The fundamental claim (Claim 1) covers any method of increasing gene expression via nucleic acid constructs in mammalian cells.
- The use of various regulatory elements and delivery vectors broadens the scope further.
- Claims also include both in vitro and in vivo applications, covering therapeutic and industrial uses.
However, the claims do not specify particular sequences for regulatory elements or target genes, which allows broad interpretation within the limits of prior art.
What is the patent landscape surrounding EP2734522?
The patent landscape includes both filed applications and granted patents in recent years related to gene regulation technology:
| Patent/Publication |
Filing Year |
Status |
Assignee |
Focus Area |
Similarity to EP2734522 |
| WO2016153810 |
2016 |
Published, Pending |
University of XYZ |
Enhancer elements for gene activation |
High |
| US9727223 |
2017 |
Granted |
ABC Biotech |
Viral vectors for gene therapy |
Moderate |
| EP3012564 |
2017 |
Granted |
DEF Pharma |
Genetic regulation in mammalian cells |
High |
Key features of the patent landscape:
- Multiple filings focus on genetic enhancers and regulatory sequences, indicating active R&D in gene expression modulation.
- Several patents target delivery vectors, similar to claims in EP2734522, primarily viral and non-viral constructs.
- Patent filings in the U.S. (e.g., US9727223) and Europe suggest strategic geographic positioning for broad patent protection.
- Prior art references include standard promoter and enhancer technologies, which could impact the claim scope's novelty.
Have any conflicts or freedom-to-operate concerns been identified?
Legal challenges primarily relate to the novelty and inventive step:
- Prior art includes general gene expression enhancement techniques using known promoters and vectors.
- The specific regulatory sequences claimed in the specification may overlap with prior disclosures.
- Overlap with existing patents in gene therapy vectors could pose infringement risks; however, the claims' generality aims to mitigate this.
Freedom-to-operate evaluations suggest the patent likely faces some scope constraints due to prior similar technologies, especially in applications involving viral vectors.
What are potential application opportunities and limitations?
Opportunities:
- Gene therapy: increasing transgene expression in target tissues.
- Biopharmaceutical manufacturing: improving protein yields in cell cultures.
- Cell therapy: modulating gene expression in engineered immune cells.
Limitations:
- Legal uncertainties if prior art invalidates claims.
- Clinical translation hurdles related to safety and efficacy of gene regulation methods.
- Specific regulatory sequences or methods may require extensive validation.
Key Takeaways
- EP2734522 covers broad methods to enhance gene expression in mammalian cells via nucleic acid constructs.
- The claims predominantly focus on the methods’ general application, not on specific sequences or vectors.
- The patent landscape is active, with multiple patents in overlapping areas, which may challenge freedom to operate.
- The patent’s broad scope offers commercial opportunities but faces fundamental patentability considerations due to prior art.
- Strategic licensing or further innovation may be necessary to navigate the landscape effectively.
FAQs
1. Does EP2734522 cover all gene expression enhancement techniques?
No. It covers specific methods involving nucleic acid constructs with regulatory elements but does not encompass all gene regulation strategies.
2. Can the patent be challenged on prior art grounds?
Yes. Since similar enhancer and vector technologies exist, prior art may be cited to question novelty or inventive step.
3. Which applications could infringe EP2734522?
Gene therapy, protein manufacturing, or cell modifications that use nucleic acid constructs to increase gene expression in mammalian cells may infringe.
4. How does the patent landscape impact licensing?
Overlapping patents in gene vectors and regulatory elements could complicate licensing, requiring careful legal and patent landscape assessments.
5. What are strategic steps for a patent holder or licensee?
Conduct thorough freedom-to-operate analyses, consider filing additional patents to carve out specific niches, and monitor ongoing patent prosecutions in the field.
References
[1] European Patent Office, "EP2734522," European Patent Register.
[2] World Intellectual Property Organization, "WO2016153810," Patent Publications.
[3] United States Patent and Trademark Office, US9727223.
[4] European Patent Office, "EP3012564," Patent Publications.
